Company Overview and News
New Zealand shares dipped, led lower by Sky Network Television and Tourism Holdings, but gained over 4 per cent in the month after a busy earnings season.
TME TRMEF AIR FCREY RYM WHGPF ANZFY AIZ FTRRF CGF WHS SKT SYKWF WHOSY TME SKKTY SML FBU RHCGF THO FRCEF FBU THL ANZLY RYHTY ANZFF TDMEY
New Zealand shares dropped as investors picked a weaker outlook for Air New Zealand and Ebos. Fisher & Paykel Healthcare Corp and Auckland International Airport gained on expectations for continuing strong earnings growth.
TME AIA TRMEF WBC AIR SPKKY NZTCY SPK NZTCF WEBNF WBK ACKDF ANZFY AUKNY AIZ AIA WBC PPSHY ANZLY TME ANZFF TDMEY
New Zealand shares hit another record amidst a slew of earnings, with Trade Me Group and A2 Milk Co gaining on their annual accounts while Fletcher Building dropped.
TME TRMEF FBU WBC FCREY SPKKY NZTCY SPK NZTCF WEBNF WBK FRCEF WBC PPSHY FBU TME TDMEY MEZ
Trade Me Group is distributing $100 million via a 22 cents per share special dividend, as the online auction company announced it turned over more than $250 million for the first time to deliver a 3.9 per cent increase in net profit for the year to June 30 of $96.6 million.
TME TRMEF TME TDMEY
New Zealand shares gained on continued market strength from the weaker Kiwi dollar, led higher by Trade Me Group and A2 Milk Co, while Fonterra Shareholders Fund dropped as its expected final dividend was removed.
TME TRMEF FBU FBU FCREY TME SKLUY SKL TDMEY FRCEF FTRRF
New Zealand shares rose, led higher by Comvita and Kathmandu Holdings, while Fisher and Paykel Healthcare Corp and Trade Me Group fell.
KTHDY TME TRMEF AIR ZNRGF ZEL ANZFY AIZ FTRRF KMD SKT ZNZ SYKWF THL ANZLY TME SKKTY ANZFF TDMEY KMD
New Zealand shares dropped as heightened global trade tensions weighed across Asian equity markets, led lower by Pushpay Holdings and Trade Me Group while Kathmandu Holdings gained again following its upgrade yesterday.
KTHDY TME GNE TRMEF PPSHY TME GNE TDMEY KMD MEZ GEL KMD
Trade Me Group chief executive Jon Macdonald intends to step away from the company that operates New Zealand's top online marketplace in about six months, leaving a position he held for more than a decade and a company he joined in 2003.
TME TRMEF TME TDMEY
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.
CEN TME TRMEF PYIYY AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF TME CEN KMD KTHDY AIA FBU WBC SPKKY NZTCY SPK WEBNF WBK FRCEF COENY AIA WBC FBU ANZLY MPP MTPGF ANZFF TDMEY MEZ PFI
New Zealand shares were mixed in light trading ahead of tomorrow's public holiday, with A2 Milk Co and Synlait Milk continuing to weaken while Fisher and Paykel Healthcare Corp rebounded and Fletcher Building extended gains.
TME TRMEF FBU FCREY ZNRGF FRCEF ZEL ZNZ GNE FBU TME GNE TDMEY GEL SML
New Zealand shares gained as the US earnings season helped lift sentiment toward equities. Growth-linked companies including Synlait Milk, A2 Milk, Comvita led gains in the local market.
TME TRMEF FBU RHCGF FCREY RYM FRCEF FBU TME RYHTY TDMEY MS SML
New Zealand shares rose as the local bourse joined a region-wide rally on optimism the US and China will manage to avoid a trade war that could slow global growth. Sky Network Television, Fisher & Paykel Healthcare and Spark NZ led broad-based gains. Orion Health jumped 11 per cent.
TME TRMEF FBU FCREY FRCEF SKT SYKWF PPSHY FBU TME SKKTY TDMEY SML
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:TME / TRADE ME GROUP LIMITED on message board site Silicon Investor.